The role of boron and its compounds in preventing osteoarticular diseases
pdf

Keywords

osteoarticular diseases,
boron,
boron compounds osteoarticular diseases,
boron compounds.

How to Cite

RACU, M.-V., SCOREI, I. R. and PINZARU, I. (2021) “The role of boron and its compounds in preventing osteoarticular diseases”, One Health & Risk Management , 2(4S), p. 61. Available at: https://journal.ohrm.bba.md/index.php/journal-ohrm-bba-md/article/view/230 (Accessed: 26June2025).

Abstract

Introduction. Boron is a trace mineral that is supposed to be essential for human health. Organic boron compounds, which can be found in vegetable products are highly bioavailable for humans and can positively influence minerals such as calcium, phosphorus, magnesium and act in synergy with vitamin D, which are known to be beneficial for osteoarticular health. The aim of this study was to research the literature to determine the role of boron in preventing osteoarticular diseases.

Material and methods. This present paper analyzed 126 bibliographic sources that highlighted the boron and its compounds functions, as well as their role in preventing osteoarticular diseases.

Results. Boron is important for osteogenesis and its deficiency can lead to impaired growth and abnormal bones development. It supports bone health in postmenopausal women by reducing urinary loss of the minerals such as calcium, magnesium and phosphorus, which are essential for bone building. Boron supplementation can decrease calcitonin blood levels and increase levels of calcium and vitamin D at the same time.

According to recently published researches, people older than 40 can prevent and/or correct arthritis, osteoporosis and osteoarthritis by taking boron to or higher than 3 mg per day. In countries where soil was depleted of boron and daily intake of this mineral was 1 mg or lower, the incidence of arthritis was between 20 and 70%. Contrary to this, in countries where daily boron intake was 3 to 10 mg per day, the incidence of arthritis ranged from 0 to 10%. 

A low serum level of boron was found in individuals with both rheumatoid arthritis and osteoarthritis. Low serum levels of this mineral were correlated with higher levels of rheumatoid factor, the antibody that causes destruction of the joints in both diseases. Studies that were done in the Middle East demonstrate that patients with rheumatoid arthritis have 50% lower serum boron than controls. This may suggest that boron can play a role in pathophysiology of rheumatoid arthritis and osteoarthritis and their severity.

Boron, as well as zinc, manganese, magnesium and aluminum, is present in the mineralized and non-mineralized portion of bones, although their role in bone functioning is not completely understood. Following these, one study has shown that boron levels were reduced in patients with osteoarthritis of the hip. 

Calcium fructoborate, the most studied bioactive boron compounds, could be effective in reducing joint discomfort and stiffness, as well as in helping to reduce the need for use of non-steroidal anti-inflammatory drugs. It can significantly improve knee discomfort during a 2-week period when compared to placebo. Additionally, it synergizes with dexamethasone to increase the bone mineralization.

Conclusions. Boron can affect bone metabolism. An adequate intake of minimum 3 mg of boron per day is particular important for patients with rheumatoid arthritis, osteoarthritis or osteoporosis and even more important for individuals who are at high risk of developing these conditions.

pdf

|Views: 6171| |pdf Downloads: 103|


pdf
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Downloads

Download data is not yet available.

ANNOUNCEMENT

Starting from July 1, 2025, the article processing fee will be 20 EUR (or the equivalent in MDL at the official exchange rate of the National Bank of Moldova). The publication fee for an accepted article will be 150 EUR (or the equivalent in MDL).

Details here:

Processing Fee
A processing fee of 20 EUR (or the equivalent in MDL) will be charged for articles accepted for scientific review by the editorial committee of the One Health and Risk Management journal.
Note: This fee will only be charged if your article has been technically reviewed and accepted.

Publication Fee
Starting from 01.07.2025, a fee of 150 EUR (or the equivalent in MDL) will be charged for articles accepted for publication.
Additionally, authors will bear the cost of English language editing/translation services if the manuscript requires intervention. The fee is 5 EUR (or the equivalent in MDL) per page edited/translated.
The total cost for English editing/translation services will be communicated by the Editorial Board after the manuscript is accepted for publication.

Payment Details:
Payments should be made in MDL to the bank account opened in the name of the Biosafety and Biosecurity Association of the Republic of Moldova.
The invoice will be issued by the end of the month in which the payment was made.

Organization: Biosafety and Biosecurity Association of the Republic of Moldova
Address: 5C A. Cozmescu Street
Fiscal Code: 1017620004120
Bank Code (SWIFT): AGRNMD2X451
IBAN: MD34AG000000022513622370